Samsung Biologics is at the forefront of enhancing the late-stage discovery process for biologics development. By leveraging advanced proprietary platforms, the company effectively addresses the challenges associated with transitioning from research to development. This innovative approach enables faster and more efficient therapeutic antibody discovery, catering specifically to the needs of modern biopharmaceutical development.
Proprietary Discovery Technologies
Samsung Biologics employs three cutting-edge platforms that facilitate the advancement of bispecific antibodies and preclinical biologics development. These platforms include the S-DUAL® bispecific antibody platform, the DEVELOPICK® rapid developability assessment, and the S-CHOsient™ transient expression system. By optimizing workflows, Samsung ensures that potential scale-up challenges are identified and resolved early, allowing clients to expedite their journey to market.
S-DUAL® Bispecific Antibody Platform
The S-DUAL® platform is designed to produce IgG-like bispecific antibodies with remarkable purity exceeding 95%. This technology enables precise pairing of heavy and light chains, streamlining the pathway towards therapeutic development. The ability to create dual-specificity antibodies not only accelerates commercialization but also minimizes the risk associated with low immunogenicity. This platform is a cornerstone of Samsung’s commitment to fostering successful biologics development.
DEVELOPICK® Rapid Developability Assessment
DEVELOPICK® serves as an efficient drug candidate screening platform, capable of evaluating biologics within a mere month. It requires minimal material (only 80 mg) while delivering crucial insights about a candidate’s stability, solubility, and formulation potential. Key features of this platform include primary structure assessments, relative solubility tests, and stress treatments to gauge performance under various conditions. Such comprehensive analysis empowers informed, cost-effective decision-making, aligning with the goals of both analytical development and manufacturing processes.
Insights from DEVELOPICK®
The unique capabilities of DEVELOPICK® extend beyond mere assessment. It predicts which candidates possess the highest potential for further advancement by proposing optimal formulations and scoring candidates based on their stability profiles. This predictive power enhances strategic planning in drug development, ensuring that resources are allocated effectively.
S-CHOsient™ Transient Expression System
The S-CHOsient™ transient expression system is another vital component of Samsung Biologics’ late discovery services. This platform supports the generation of molecules at an early stage and bolsters CHO cell transient expression workflows. Researchers can utilize this system to produce materials for internal studies, test different vector ratios for transfection, and create reference materials essential for process development. The system’s robust productivity and quality standards accelerate therapeutic antibody discovery, further enhancing the efficiency of the overall development pipeline.
Seamless Integration for Scalability
The integration of these advanced platforms not only supports the discovery phase but also lays the groundwork for scalability in manufacturing. By ensuring that all processes are aligned, from quality assurance to drug substance manufacturing, clients can expect a cohesive and streamlined journey from discovery to market.
Conclusion
In the fast-paced world of biopharmaceuticals, Samsung Biologics stands out with its innovative late discovery services. By harnessing proprietary platforms, the company drives efficiency in biologics development, empowering clients to bring their life-saving therapies to market swiftly. The combination of advanced technologies and strategic insights positions Samsung Biologics as a leader in the evolving landscape of therapeutic discovery.
- Accelerated Development: Proprietary platforms streamline the transition from research to market.
- High Purity: S-DUAL® platform ensures >95% purity in bispecific antibodies.
- Rapid Assessment: DEVELOPICK® offers quick evaluation of drug candidates with minimal material.
- Predictive Insights: DEVELOPICK® aids in identifying the best candidates for advancement.
- Robust Expression: S-CHOsient™ enhances early-stage molecule generation and quality.
- Seamless Scalability: Integrated systems promote efficient scaling from discovery to manufacturing.
Read more → samsungbiologics.com